Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

Shares of Septerna SEPN surged 51% on May 14 after the company entered into an exclusive global collaboration and license ...

CompanyOverview|NYSE:NVO] Despite a double beat in its quarterly earnings on May 7, Novo Nordisk A/S (NYSE: NVO) stock is ...

As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

While M&A activity slowed in the first quarter of 2025, including in life sciences, there have been plenty of noteworthy developments in the ...

Gov. Josh Shapiro warned Wednesday that the Medicaid cuts Congress is considering would mean billions of dollars in lost federal aid to ...